Out-of-pocket obesity drugs drives Lilly profits
The willingness of people to pay for weight loss medications out of pocket has helped Eli Lilly beat analyst expectations again to report $34.3 billion (US$24.4 billion) in revenue for the third quarter of this year.
To see the whole article, log in or create an account.